Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Invested Capital (2016 - 2025)

China Pharma Holdings' Invested Capital history spans 16 years, with the latest figure at $24.7 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 177.94% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $24.7 million, up 177.94%, while the annual FY2025 figure was $24.7 million, 177.94% up from the prior year.
  • Invested Capital reached $24.7 million in Q4 2025 per CPHI's latest filing, up from $10.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $24.7 million in Q4 2025 to a low of $4.7 million in Q4 2022.
  • Average Invested Capital over 5 years is $9.0 million, with a median of $8.2 million recorded in 2024.
  • Peak YoY movement for Invested Capital: crashed 54.29% in 2022, then soared 177.94% in 2025.
  • A 5-year view of Invested Capital shows it stood at $10.3 million in 2021, then crashed by 54.29% to $4.7 million in 2022, then skyrocketed by 79.39% to $8.5 million in 2023, then rose by 4.8% to $8.9 million in 2024, then skyrocketed by 177.94% to $24.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Invested Capital are $24.7 million (Q4 2025), $10.3 million (Q3 2025), and $7.9 million (Q2 2025).